Y-Mabs Therapeutics (YMAB) just unveiled an update.
Bo Kruse, the Chief Financial Officer of Y-mAbs Therapeutics, has announced his resignation, effective once a successor is appointed and starts working with the company, with a final departure date of July 31, 2024. He will remain as a non-executive employee if his successor begins before this date to ensure a smooth transition. His resignation is not due to any disputes with the company’s operations or practices. The company has publicly announced his resignation, emphasizing that it will not impact their legal standings or filings.
For a thorough assessment of YMAB stock, go to TipRanks’ Stock Analysis page.
